Core Insights - Catalyst Pharmaceutical (CPRX) reported $122.71 million in revenue for Q2 2024, a year-over-year increase of 23.2% [1] - The earnings per share (EPS) for the same period was $0.56, up from $0.33 a year ago, indicating a strong performance [1] - The reported revenue exceeded the Zacks Consensus Estimate of $111.76 million by 9.80%, and the EPS also surpassed the consensus estimate of $0.42 by 33.33% [1] Revenue Breakdown - Product revenue, net was $122.65 million, compared to the average estimate of $111.57 million from five analysts [3] - License and other revenue was $0.06 million, falling short of the average estimate of $0.32 million from three analysts [4] - FYCOMPA product revenue, net reached $36.54 million, exceeding the average estimate of $33.21 million from two analysts [5] - AGAMREE product revenue, net was $8.75 million, surpassing the average estimate of $5.98 million from two analysts [6] - FIRDAPSE product revenue, net totaled $77.37 million, compared to the average estimate of $72.53 million from two analysts [7] Stock Performance - Catalyst shares have returned +3.7% over the past month, contrasting with the Zacks S&P 500 composite's -5.9% change [7] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [7]
Catalyst (CPRX) Reports Q2 Earnings: What Key Metrics Have to Say